ImaginAb Collaborates with Three Global Pharmaceutical Companies Focusing on the Development of its CD8 ImmunoPET Technology

 ImaginAb Collaborates with Three Global Pharmaceutical Companies Focusing on the Development of its CD8 ImmunoPET Technology

ImaginAb Collaborates with Three Global Pharmaceutical Companies Focusing on the Development of its CD8 ImmunoPET technology

Shots:

  • ImaginAb signs a multi-year agreement with AstraZeneca, Pfizer & Takeda for the development of ImaginAb’s CD8 ImmunoPET technology. The global companies will get early access to clinical and imaging data & will contribute in post-trial data analysis in exchange for helping ImaginAb’s current clinical studies
  • The focus of the agreement is to streamline the clinical development of next-generation cancer immunotherapies and to further develop CD8 ImmunoPET as a pharmacodynamic marker for use in drug development
  • ImaginAb’s technology utilizes its Minibody’ platform to target & visualize CD8+ T cells & is used for non-invasive PET imaging of CD8 T cells in patients, providing highly-specific, quantitative assessment of the immunological status of each cancer lesion within a patient thus enabling the quick treatment meeting the need of patients

Click here to­ read full press release/ article | Ref: ImaginAb | Image: LinkedIn

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post